Clinical Trials Logo
  1. Home
  2. CMV
  3. NCT04392297

Clinical and Immunological Features of the CMV Infection Atypical Course in Immunocompetent Individuals

CMV Clinical Trial

Official title:
To Identify the Clinical and Immunological Features of the CMV Infection Atypical Course in Immunocompetent Individuals and to Develop Methods for the Diagnosis and Treatment of Patients in This Category

Clinical Trial Summary

Current study evaluates possible correlations between the content of various cell populations, the genetic material of the virus and antibodies to it in the blood of patients and the risk of thrombosis development in patients with acute CMV infection. А new method for the early detection of immunological and clinical signs of thromboembolic complications of CMV infection in immunocompetent individuals and the treatment of patients in this category will be developed.

Clinical Trial Description

- evaluate the immune status main indicators that characterize the activation of immune system, immunosuppression and anergy (myeloid suppressor cells, T-regulatory cells, T-cells according to the stages of differentiation (naive - effector - memory), activated T-cells); - identify and characterize immunological disorders in patients with CMV infection complicated by thromboembolism of various localization; - determine the presence and quantitative content in plasma / serum and neutrophils of the CMV genetic material by real-time PCR; - study humoral immunity to CMV (IgM / IgG antibodies to CMV in serum); - determine the content of CMV specific T-cells in peripheral blood; - develop a method for the early detection of immunological and clinical signs of thromboembolic complications of CMV infection in immunocompetent persons and treatment of patients in this category. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04392297
Study type Observational
Source The Republican Research and Practical Center for Epidemiology and Microbiology
Contact
Status Enrolling by invitation
Phase
Start date July 1, 2019
Completion date November 30, 2024
View Details
See also
  Status Clinical Trial Phase
Enrolling by invitation NCT04101136 - Effect of Atorvastatin on Subclinical Atherosclerosis N/A
Recruiting NCT06001320 - De-novo Initiation of Letermovir vs Valganciclovir for Cytomegalovirus Prophylaxis in AA Kidney Trans Recip Early Phase 1
Completed NCT01923766 - Cytotoxic T Cells to Prevent Virus Infections Phase 1
Not yet recruiting NCT05969743 - Letermovir Prophylaxis for Cytomegalovirus (CMV) in Patients With Graft-versus-host Disease Phase 2
Recruiting NCT01011712 - The Natural History of Severe Viral Infections and Characterization of Immune Defects in Patients Without Known Immunocompromise
Recruiting NCT06034925 - Maribavir vs. Valganciclovir for CMV Prophylaxis in High-Risk Kidney Transplant Recipients Phase 4
Completed NCT04840199 - A Study to Evaluate the Anti-inflammatory Effects of Letermovir (Prevymis) in Adults With Human Immunodeficiency Virus (HIV)-1 and Asymptomatic Cytomegalovirus (CMV) Who Are on Suppressive Antiretroviral Therapy, Plus Its Effect on Chronic Inflammation, HIV Persistence and Other Clinical Outcomes. Phase 2
Terminated NCT03502161 - Clinical Evaluation of the QuantiFERON CMV Assay
Not yet recruiting NCT06211543 - Letermovir (LMV) Prophylaxis in CMV-seronegative Allogeneic Stem Cell Transplant Recipients With CMV Seropositive Donors: an Exploratory Study From Spanish GETH/TC Centers
Recruiting NCT04056533 - Prophylaxis of Cytomegalovirus Infection With Adoptive Cell Inmunotherapy Phase 2
Not yet recruiting NCT04280380 - Cytomegalovirus Infection in Critically Ill Patients and Patients Receiving Anticancer Therapy
Active, not recruiting NCT03924219 - CMV T Cell Immunity in Pediatric Solid Organ Transplant Recipients
Not yet recruiting NCT06453460 - Prospect Eval of Efficacy of CMV-TCIP Direct Letermovir Prophylax After Allogen Hemato Cell Transpla Phase 2
Completed NCT02694484 - Search Cytomegalovirus in Healthy Volunteers Stools Samples Selected as Potential Donor for Fecal Microbiota Transplant N/A
Recruiting NCT06011486 - Expansion of Virus-Specific Lymphocytes for Cell Therapy Phase 1
Recruiting NCT04017962 - A Study of the Drug Letermovir (LTV) as Prevention for Recurrent of Cytomegalovirus (CMV) Infection Phase 2
Terminated NCT03570411 - Evaluating the Clinical Utility of the T-SPOT.CMV Assay for the Prediction of CMV Reactivation Among Pediatric Patients Undergoing Hematopoietic Cell Transplant
Completed NCT00872703 - Does Normal Brain Imaging Predict Normal Neurodevelopmental Outcome in Fetuses With Proven Cytomegalovirus Infection? N/A
Active, not recruiting NCT01945814 - Allogeneic Multivirus - Directed Cytotoxic T Lymphocytes (CTL) Phase 1
Recruiting NCT05041426 - Letermovir for CMV Prevention After Lung Transplantation Phase 2